Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers

Fig. 4

Challenges faced by liquid biopsy and PGx for their implementation in clinical practice for EGFR resistant and mutant lung cancer patients. Abbreviations: PGx: Pharmacogenomics; EGFR: Epidermal growth factor receptor; TKIs: Tyrosine kinase inhibitors; PTM: Post translational modifications; DDI: Drug-drug interaction; MRD: Minimal residual disease; TMB: Tumor mutational burden

Back to article page